Table 1.
Clinical characteristics of patients with advanced lung adenocarcinoma eligible for further analysis.
| Variable | With available data on EGFR mutation (n = 517) | With available data on CEAPd (n = 288) |
|---|---|---|
| Age (years)* | 66 [59, 77] | 64.5 [58, 73.8] |
| Age | ||
| <65 years | 231 (44.7%) | 144 (50.0%) |
| ≥65 years | 286 (55.3%) | 144 (50.0%) |
| Sex | ||
| Female | 275 (53.2%) | 165 (57.3%) |
| Male | 242 (46.8%) | 123 (42.7%) |
| Stage | ||
| IIIB | 84 (16.2%) | 47 (16.3%) |
| IV | 433 (83.8%) | 241 (83.7%) |
| Smoking | ||
| Never | 336 (65.0%) | 198 (68.8%) |
| Ever | 181 (35.0%) | 90 (31.3%) |
| EGFR | ||
| Wild-type | 190 (36.8%) | 94 (32.6%) |
| Mutant | 327 (63.2%) | 194 (67.4%) |
| CEAIn | ||
| <5 ng/mL | 199 (38.5%) | 96 (33.3%) |
| 5–100 ng/mL | 215 (41.6%) | 134 (46.5%) |
| >100 ng/mL | 103 (19.9%) | 58 (20.1%) |
| CEAPd | ||
| <5 ng/mL | NA | 92 (31.9%) |
| 5–100 ng/mL | NA | 126 (43.8%) |
| >100 ng/mL | NA | 70 (24.3%) |
| Follow-up Months* | 15.4 [8.3, 25.5] | 20.8 [13, 32.8] |
EGFR, epidermal growth factor receptor; CEAIn, serum CEA level at initial diagnosis; CEAPd, serum CEA level at disease progression; NA, not applicable.
*Data were presented as median [25th and 75th percentiles].